Neuronetics, Inc. (STIM)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 49 | 55 | 65 | 71 | 75 | 149 | 155 | 162 |
| Operating profit | $m | -31 | -23 | ||||||
| Net profit | $m | -27 | -31 | -37 | -30 | -44 | -39 | -30 | -23 |
| EPS reported | $ | -0.59 | -0.43 | ||||||
| Operating cashflow per share | $ | -0.31 | -0.13 | ||||||
| Capex per share | $ | 0.01 | 0.01 | ||||||
| FCF per share | $ | -0.32 | -0.14 | ||||||
| Free cash flow | $m | -21 | -10 | ||||||
| Net debt | $m | 37 | 42 | ||||||
| Book value equity | $m | 22 | 18 | ||||||
| Book value per share | $ | 0.34 | 0.25 | ||||||
| Number of shares | m | 65.95 | 71.37 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 4.07 | 5.10 | ||||||
| P/S LTM | x | 0.61 | 0.59 | ||||||
| P/FCF LTM | x | -4.30 | -9.03 | ||||||
| EV/EBITDA LTM | x | -5.43 | -6.93 | ||||||
| EV/Sales LTM | x | 0.99 | 1.91 | ||||||
| Earnings Yield LTM | % | -42.85% | -12.92% | ||||||
| FCF Yield | % | -23.27% | -11.07% | ||||||
| Quality | |||||||||
| ROE | % | -174.27% | -150.56% | ||||||
| ROIC | % | -26.96% | -21.10% | ||||||
| Operating margin | % | -21.08% | -14.74% | ||||||
| Gross margin | % | +48.48% | +49.12% | ||||||
| FCF/Sales | % | -14.20% | -6.50% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +99.17% | +107.10% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.23 | -0.12 | ||||||
| Net Debt/EBITDA | x | -2.07 | -3.17 | ||||||
| EBIT/Net interest | x | -3.74 | -2.67 | ||||||
| Net debt/market cap | % | +78.42% | +26.79% | ||||||
| Net debt/Equity | x | 1.65 | 2.36 | ||||||
| Gross debt/equity | x | 4.04 | 4.85 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Neuronetics, Inc. functions as a medical technology enterprise with commercialized products, specializing in the creation, enhancement, and global distribution of solutions for individuals experiencing neurohealth conditions, both within the U.S. and abroad. The company's flagship product is the NeuroStar Advanced Therapy System, an in-office, non-surgical, and non-pharmaceutical treatment option available for adult patients diagnosed with major depressive disorder. This sophisticated system utilizes transcranial magnetic stimulation (TMS) to generate a pulsed magnetic field, similar in strength to an MRI, which subsequently induces electrical currents. These currents are specifically engineered to activate brain areas that are key to mood regulation. Neuronetics distributes its offerings directly to psychiatrists through its dedicated sales and client support personnel. Established in 2001, the company's corporate headquarters are situated in Malvern, Pennsylvania.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Neuronetics, Inc. functions as a medical technology enterprise with commercialized products, specializing in the creation, enhancement, and global distribution of solutions for individuals experiencing neurohealth conditions, both within the U.S. and abroad. The company's flagship product is the NeuroStar Advanced Therapy System, an in-office, non-surgical, and non-pharmaceutical treatment option available for adult patients diagnosed with major depressive disorder. This sophisticated system utilizes transcranial magnetic stimulation (TMS) to generate a pulsed magnetic field, similar in strength to an MRI, which subsequently induces electrical currents. These currents are specifically engineered to activate brain areas that are key to mood regulation. Neuronetics distributes its offerings directly to psychiatrists through its dedicated sales and client support personnel. Established in 2001, the company's corporate headquarters are situated in Malvern, Pennsylvania.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free